365
Participants
Start Date
December 18, 2017
Primary Completion Date
May 27, 2020
Study Completion Date
December 21, 2020
Lenabasum 5 mg
Subjects will receive lenabasum 5 mg twice daily.
Lenabasum 20 mg
Subjects will receive lenabasum 20 mg twice daily.
Placebo oral capsule
Subjects will receive placebo twice daily.
St Vincent's Hospital, Melbourne
Royal Adelaide Hospital, Adelaide
Columbia University Medical Center, New York
Hospital for Special Surgery, New York
The Steffens Scleroderma at The Center for Rheumatology, Albany
UPMC Arthritis and Autoimmunity Center, Falk Clinic, Pittsburgh
University of Pennsylvania Health System - PCAM, Dept. of Rheumatology, Philadelphia
Georgetown University Medical Center, Washington D.C.
John Hopkins University, Scleroderma Center, Baltimore
Medical University of South Carolina, Charleston
University of Toledo, Toledo
Cleveland Clinic, Cleveland
Michigan Medicine, Ann Arbor
Medical College of Wisconsin/Froedtert Hospital, Milwaukee
University of Minnesota Health Clinical Research Unit, Minneapolis
Northwestern University, Chicago
Universitätsklinikum Heidelberg, Heidelberg
Tulane University Medical Center, New Orleans
Metroplex Clinical Research Center, Dallas
UTP Rheumatology Clinic, Houston
University of Colorado Anschutz Medical Campus, Aurora
University of Utah Hospitals and Clinics, Salt Lake City
Pacific Arthritis Care Center, Los Angeles
UCLA, Los Angeles
University of California San Diego, La Jolla
Stanford University, Palo Alto
Rambam Health Corporation, Haifa
Massachusetts General Hospital, Division of Rheumatology, Boston
Boston University Medical Center (BUMC) - General Clinical Research Unit (GCRU), Boston
Dartmouth Hitchcock Medical Center, Lebanon
Rutgers Clinical Research Center, Robert Wood Johnson Medical School, New Brunswick
Liverpool Hospital, Liverpool
Royal Prince Alfred Hospital, Sydney
Sir Mortimer B. Davis Jewish General Hospital, Montreal
The Arthritis Centre, Winnipeg
Charité- Universitätsmedizin Berlin, Klinik für Rheumatologie und Klinische Immunologie, Abteilung -Neue Therapien & Studien-, Berlin
University Hospital Cologne, Department of Dermatology and Venereology, Cologne
Universitätsklinik Köln,Klinik und Poliklinik für Dermatologie und Venerologie, Cologne
Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen
University Medical Center Freiburg, Freiburg im Breisgau
Kerckhoff-Klinik GmbH, Zentrum Rheumatologie u. Klin. Immunologie, Studienambulanz, Nauheim
University Hospital Ulm, Ulm
Bnai Zion Medical Center, Haifa
Meir Medical Center - Internal Medicine E, Kfar Saba
Sheba Medical Center, Ramat Gan
Kyushu University Hospital, Fukuoka
Kanazawa University Hospital, Kanazawa
Gunma University Hospital, Maebashi
Hokkaido University Hospital, Sapporo
National University Corporation Tohoku University Tohoku University Hospital, Sendai
Osaka University Hospital, Suita
Nippon Medical School Hospital, Tokyo
Yokohama City University Hospital, Yokohama
Leiden University Medical Center, Leiden
Erasmus Medical Center, Rotterdam
Haga Hospital, The Hague
Samodzielny Publiczny Szpital Kliniczny nr 1; Katedra i Klinika Dermatologii, Wenerologii i Dermatologii Dziecięcej Uniwersytetu Medycznego w Lublinie, Lublin
Medyczne Centrum Hetmanska, Poznan
Reum-Medica S.C, Wroclaw
Hanyang University Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Hospital Universitari de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Doctor Peset, Valencia
Cantonal Hospital St. Gallen, Sankt Gallen
University Hospital Zurich, Zurich
Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds
Guy's and St.Thomas' NHS Foundation Trust, London
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Ninewells Hospital, Dundee
Freeman Hospital, Newcastle
Russell's Hall Hospital, Dudley
Royal Free Hospital London NHS Foundation Trust, London
Salford Royal NHS Foundation Trust, Salford
Lead Sponsor
Corbus Pharmaceuticals Inc.
INDUSTRY